Neuronal oxidative damage from activated innate immunity is EP2 receptor-dependent

Journal of Neurochemistry

Volumn 83, Issue 2, 2002, Pages 463-470

  Montine, Thomas J ^a,b,d   Milatovic, Dejan ^a   Gupta, Ramesh C ^c   Valyi Nagy, Tibor ^b   Morrow, Jason D ^a,b   Breyer, Richard M ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MURRAY STATE UNIVERSITY   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Excitotoxicityinnate immunity; Isoprostanes; Neuroprostanes; NSAIDs; Prostaglandin E2

Indexed keywords

ARACHIDONIC ACID; BIOLOGICAL MARKER; DOCOSAHEXAENOIC ACID; IBUPROFEN; INDOMETACIN; ISOPROSTANE; KAINIC ACID; LIPOPOLYSACCHARIDE; NEUROPROSTANE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; PROSTANOID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INJURY; CONTROLLED STUDY; ENZYME ACTIVITY; IMMUNITY; IMMUNOSTIMULATION; LIPID PEROXIDATION; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; RECEPTOR UPREGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; BIOLOGICAL MARKERS; BRAIN CHEMISTRY; CITRULLINE; DISEASE MODELS, ANIMAL; DOCOSAHEXAENOIC ACIDS; F2-ISOPROSTANES; IMMUNITY, NATURAL; ISOPROSTANES; KAINIC ACID; LIPID PEROXIDATION; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; NEURONS; OXIDATION-REDUCTION; OXIDATIVE STRESS; RECEPTORS, PROSTAGLANDIN E;

ANIMALIA;

EID: 0036798125     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2002.01157.x     Document Type: Article

References (54)

1. 2 protects cultured cortical neurons against N-methyl-D-aspartate-mediated glutamate cytotoxicity. Brain Res. 663, 237-243.
2. 2 on tumor necrossi factor and interleukin 10 production in microglia: a regulatory loop controlling microglia pro- and anti-inflammatory activities. J. Neurosci. Res. 56, 571-580.
3. Andersen K., Launer L., Ott A., Hoes A., Breteler M. and Hofman A. (1995) Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam study. Neurology 45, 1441-1445.
4. Andrew P. and Mayer B. (1999) Enzymatic function of nitric oxide synthases. Cardiovasc Res. 43, 521-531.
5. Asanuma M., Nishibayashi-Asanuma S., Miyazaki I. and Kohno M. (2001) Neuroprotective effects of non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals. J Neurochem. 76, 1895-1904.
6. Bagetta G., Rodino P., Paoletti A., Arabia A., Massoud R. and Nistico G. (1995) Systemic administration of lithium chloride and tacrine but not kainic acid augements citrulline contrnt in rat brain. Eur J Pharmacol. 294, 314-324.
7. Beal M. F. (1998) Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Ann. Neurol. 44, S110-S114.
8. Bezzi P., Carmignoto G., Pasti L., Vesce S., Rossi D., Rizzini B., Pozzan T. and Volterra A. (1998) Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. Nature 391, 281-285.
9. 2 receptors. Proc. Natl Acad. Sci. USA 95, 15792-15727.
10. Breyer R., Bagdassarian C., Myers S. and Breyer M. (2001) Prostanoid receptors: subtypes and signaling. Ann. Rev. Pharmacol. Toxicol. 41, 661-690.
11. 2 and 4-aminopyridine prevent the lipopolysaccharide-induced outwardly rectifying potassium current and interleukin-1β production in cultured rat microglia. J. Neurochem. 70, 2357-2368.
12. Caggiano A. and Kraig R. (1999) Prostaglandin E receptor subtypes in cultured rat microglia and their role in reducing lipopolysaccharide-induced interleukin-1β production. J. Neurochem. 72, 565-575.
13. Cazevielle C., Muller A., Meynier F., Dutrait N. and Bonne C. (1994) Protection by prostaglandins from glutamate toxicity in cortical neurons. Neurochem. Int. 24, 395-398.
14. Drachman D. and Rothstein J. (2000) Inhibition of cyclo-oxygenase-2 protects motor neurons in an organotypic model of amyotrophic lateral sclerosis. Ann. Neurol. 48, 792-795.
15. Droge W. (2002) Free radicals in the physiological control of cell function. Physiol. Rev. 82, 47-95.
16. 3 receptors, regulates brain nitric oxide synthase in the perinatal period. Am. J. Physiol. 275, 1812-1821.
17. 2 receptor subtype in the rat brain: relationship to sites of interleukin-1-induced cellular responsiveness. J. Comp Neurol. 428, 5-20.
18. Floyd R. (1999) Antioxidants, oxidative stress, and degenerative neurological disorders. Proc. Soc. Exp. Biol. Med. 222, 236-245.
19. Galea E., Reis D., Fox E., Xu H. and Feinstein D. (1996) CD14-mediated endotoxin induction of nitric oxide synthase in cultured brain glia cells. J. Neuroimmunol. 64, 19-28.
20. Griffin D. E., Wesselingh S. L. and McArthur J. C. (1994) Elevated central nervous system prostaglandins in human immunodeficiency virus-associated dementia. Ann. Neurol. 35, 592-597.
21. Hamburger S. A. and McCay P. B. (1990) Spin trapping of ibuprofen radicals: evidence that ibuprofen is a hydroxyl radical scavenger. Free Rad. Res. 9, 337-342.
22. Hewett S., Uliasz T., Vidwans A. and Hewett J. (2000) Cyclo-oxygenase-2 contributes to N-methy-D-aspartate-mediated neuronal cell death in primary cortical cell culture. J. Pharm. Exp. Ther 293, 417-425.
23. Kelley K., Ho L., Winger D., Freire-Moar J., Borelli C., Aisen P. and Pasinetti G. (1999) Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclo-oxygenase-2. Am. J. Pathol. 155, 995-1004.
24. 4 is necessary for lipopolysaccharide-induced oligodendrocyte injury in the CNS. J. Neurosci. 22, 2478-2486.
25. Lerner-Natoli M., Montpied P., Rousset M. C., Bockaert J. and Rondouin G. (2000) Sequential expression of surface antigens and transcription factor NF-κB by hippocampal cells in excitotoxicity and experimental epilepsy. Epilepsy Res. 41, 141-154.
26. 2 on microglial functions. Biochimie 80, 899-904.
27. McGeer P. L., Schulzer M. and McGeer E. (1996) Arthritis and antiinflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiological studies. Neurology 47, 425-432.
28. Medzhitov R. and Janeway C. (2000) Advances in immunology: innate immunity. N. Engl. J. Med. 343, 338-344.
29. 2-isoprostane in human and experimental transmissible spongiform encephalopathies. J. Neuropathol. Exp. Neurol. 59, 866-871.
30. 2 and by cyclo-oxygenase inhibitors. Glia 19, 152-160.
31. 2, cyclic AMP, and non-steroidal antiinflammatory drugs. Eur J. Neurosci. 9, 934-940.
32. 2 synthesis by transforming growth factor-β1 and interleukin 10 in activated microglial cultures. J. Neuroimmunol. 82, 31-39.
33. Montero-Menie C., Sindji L., Pouplard A., Jehan F., Denechaud L. and Darcy F. (1994) Lipopolysaccharide intracerebral administration induces minimal inflammatory reaction in rat brain. Brain Res. 653, 101-111.
34. 2-isoprostane concentration in probable Alzheimer's disease. Neurology 52, 562-565.
35. 2-isoprostanes are increased in Alzheimer's disease. Ann. Neurol. 44, 410-413.
36. 2 levels in patients with probable Alzheimer's disease. Neurology 53, 1495-1498.
37. 3 receptor in the rat central nervous system. J Comp. Neurol. 421, 543-569.
38. 1-4 prostaglandin receptors with rat hypothalamic cell groups involved in lipopolysaccharide fever responses. J. Comp. Neurol. 428, 20-32.
39. Pace G. W. and Leaf C. D. (1995) The role of oxidative stress in HIV disease. Free Rad. Biol. Med. 19, 523-528.
40. 2 content and prevents seizures and hippocampal damage evoked by LiCl and tacrine in rat. Exp. Neurol. 149, 349-355.
41. Possel H., Noack H., Putzke J., Wolf G. and Sies H. (2000) Selective upregulation of inducible nitric oxide synthase by LPS and cytokines in microglia: in vitro and in vivo studies. Glia 32, 51-59.
42. Reich E., Markesbery W., Roberts I. I. L., Swift L., Morrow J. and Montine T. (2001) Brain regional quantification of F-ring and D/E-ring isoprostanes and neuroprostanes in Alzheimer's disease. Am. J. Pathol. 158, 293-297.
43. 2 stimulates glutamate receptor-dependent astrocyte neuromodulation in cultured hippocampal cells. J. Neurobiol. 41, 221-229.
44. 2 in mice. J. Appl. Physiol. 88, 2214-2218.
45. Stewart W. F., Kawas C., Corrada M. and Metter E. J. (1997) Risk of Alzheimer's disease and duration of NSAID use. Neurology 48, 626-632.
46. Strohmeyer R. and Rogers J. (2001) Molecular and cellular mediators of Alzheimer's disease inflammation. J. Alzheimer Dis. 3, 131-157.
47. Sugaya K., Chou S., Xu S. and McKinney M. (1998) Indicators of glial activation and brain oxidative stress after intracentricular infusion of endotoxin. Mol. Brain Res. 58, 1-9.
48. 3 in the mouse nervous system. Neuroscience 62, 919-928.
49. Thornhill J. and Smith M. (1998) Intracerebroventricular prostaglandin adminstration increases the neuronal damage evoked by global hemispheric hypoxic ischemia. Brain Res. 784, 48-56.
50. Valyi-Nagy T., Sidell K. R., Marnett L. J., Roberts I. I. L. J., Dermody T. S., Morrow J. D. and Montine T. J. (1999) Divergence of brain prostaglandin H synthase activity and oxidative damage in mice with encephalitis. J. Neuropathol. Exp. Neurol. 58, 1269-1275.
51. in'tVeld B. A., Ruitenberg A., Hofman A., Launer L. J., vanDuijn C., Stijnen T., Breteler M. and Strickler B. (2001) Non-steroidal antiinflammatory drugs and the risk of Alzheimer's disease. N. Engl. J. Med. 345, 1515-1521.
52. in'tVeld B. A., Ruitenberg A. and Launer L. J. (2000) Duration of nonsteroidal anti-inflammatory drug use and risk of Alzheimer's disease: The Rotterdam Study. Neurobiol. Aging 21, S204.
53. Weggen S., Eriksen J. L., Das P., Sagi S. A., Wang R., Pietzik C. U., Findlay K. A., Smith T. E., Murphy M. P., Butler T., Kang D. E., Sterling N., Golde T. E. and Koo E. H. (2001) A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclo-oxygenase activity. Nature 414, 212-216.
54. Xie Z., Wei M., Morgan T., Fabrizio P., Han D., Finch C. and Longo V. D. (2002) Peroxynitrite mediates neurotoxicity of amyloid β-peptide 1-42 and lipopolysaccharide-activated microglia. J. Neurosci. 22, 3484-3492.